Retatrutide Approval & Access Timeline: TRIUMPH Results, 2027 FDA Filing, No Compounding

Retatrutide (Eli Lilly investigational code LY3437943) is a triple agonist of the GIP, GLP-1, and glucagon receptors — the most-watched investigational anti-obesity drug currently in late-stage development. If you arrived searching for “GLP-3,” that is a nickname for this same molecule and not a separate drug — see what GLP-3 actually means. The Phase 2 trial^[1] reported up to 24.2% mean body-weight loss at 48 weeks at the 12 mg dose, comparable to or above the tirzepatide top-line. The Phase 3 TRIUMPH program is in late stages: TRIUMPH-4 (obesity + knee osteoarthritis) completed November 2025 with Lilly's headline “weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain.” The two main obesity trials are now published: in TRIUMPH-1, adults without diabetes lost up to 25.0% of body weight at 80 weeks,^[6] and in TRIUMPH-2, adults with type 2 diabetes lost up to 18.8%.^[7] Lilly says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027,^[8] so retatrutide will not be available by prescription in 2026. A narrow single-patient expanded access program opened in June 2026.^[9] Retatrutide is NOT currently legal to compound under FDA 503A or 503B — and the FDA has issued Warning Letters to multiple compounders in 2024-2025.

What is retatrutide?

Retatrutide is a once-weekly subcutaneous injectable peptide that activates three nutrient-sensing receptors:

• GIP (glucose-dependent insulinotropic polypeptide) receptor agonism — the same mechanism tirzepatide adds on top of pure GLP-1 action
• GLP-1 receptor agonism — the appetite/satiety/insulinotropic mechanism shared with semaglutide, liraglutide, and tirzepatide
• Glucagon receptor agonism — the differentiator. Glucagon agonism increases energy expenditure and lipolysis, theoretically adding a metabolic-rate component to the appetite-suppression mechanisms shared with other GLP-1 RAs

The triple-agonist mechanism is what drove the unusually high Phase 2 efficacy: Jastreboff et al.^[1] reported mean weight changes at 48 weeks of −22.8% on 8 mg and −24.2% on 12 mg, against −2.1% on placebo; at the 24-week primary endpoint the figures were −17.3% (8 mg) and −17.5% (12 mg) vs −1.6%. Adverse event profile is GLP-1-class consistent — GI dominant, dose-dependent. The trial population was adults with BMI ≥30 (or ≥27 with weight-related comorbidity), no T2D.

The TRIUMPH Phase 3 program — every trial verified

Lilly's Phase 3 obesity program for retatrutide is organized as the TRIUMPH program. Each trial below links to its ClinicalTrials.gov record, with the most recent primary-completion date and status^{[2][3][10][4][5]}. Numbers reflect public records as of October 2026; trial timelines can shift, so verify at the NCT URL before relying on a date.

TRIUMPH-4 is the first Phase 3 retatrutide readout. Lilly's investor headline at completion read verbatim: “Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.” Trial-design context: TRIUMPH-4 dosed retatrutide up to 12 mg/week vs placebo at 68 weeks in adults with BMI ≥27 and no diabetes, plus radiographically-confirmed knee OA. The 71.2 lb headline corresponds to the highest-dose arm; full efficacy distribution + safety detail will appear in the peer- reviewed publication.

TRIUMPH-1 and TRIUMPH-2 are the obesity-only and T2D registrational trials and are the readouts most consequential for the broader weight-management label. Both are now completed and published: TRIUMPH-2 in The Lancet and TRIUMPH-1 in the New England Journal of Medicine, both online September 29, 2026 (results below).^[6][7] TRIUMPH-3 is a separate weight-management trial in people with severe obesity and established cardiovascular disease; it completed in April 2026.^[10] Lilly's July 23, 2026 topline release reported weight loss of up to 22.6% at 80 weeks (efficacy estimand), with too few major cardiovascular events to show a difference; the full results have not yet been published in a journal.^[11]

TRIUMPH-Outcomes is the cardiovascular and renal outcomes trial — event-driven, so its primary completion date depends on accumulated MACE events rather than a fixed calendar. The 2029 estimated date reflects ClinicalTrials.gov. A successful TRIUMPH-Outcomes readout would be the basis for a cardiovascular-benefits label expansion in line with the SELECT trial pattern that landed semaglutide its cardiovascular indication post-Wegovy approval. Until then, Wegovy keeps an outcomes-data advantage that cross-trial comparisons of retatrutide and Wegovy cannot close.

Regulatory pathway: Lilly plans a BLA

Lilly's August 2026 earnings release says it plans to submit retatrutide as a Biologics License Application (BLA).^[8] (An earlier version of this article said it would be an NDA; Lilly's own filing language says BLA.) The pathway matters for what happens after launch:

• NDA-regulated drugs face Hatch-Waxman generic competition after composition-of-matter patent expiry. ANDA filers can submit Paragraph IV certifications challenging the patent, and generic versions can launch either at expiry or after litigation. This is the tirzepatide-and-semaglutide pathway.
• BLA-regulated drugs face biosimilar competition via the 351(k) pathway, which is meaningfully slower and more expensive to navigate. Biologics like dulaglutide (Trulicity) are on this pathway.

Practical implication: as a BLA product, any lower-cost copies of retatrutide would come through the biosimilar route, not as standard generics, and they are many years away. Expect brand-level pricing for the foreseeable future after launch.

Expected approval timing

Lilly's second-quarter 2026 results (August 5, 2026) say retatrutide's “clinical data package is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain,” with “plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027.”^[8] Approval then depends on the length and outcome of the FDA's review, which can be shortened if the agency grants priority review.

The phase 3 data behind the filing: TRIUMPH-1 (2,339 adults with obesity, no diabetes) found −17.6%, −23.7% and −25.0% weight change at 80 weeks on 4, 9 and 12 mg, against −3.9% on placebo, plus less knee pain and fewer sleep-apnea events in those subgroups.^[6] TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes) found −11.9%, −16.8% and −18.8%, against −5.1%.^[7] For the full results, see our TRIUMPH phase 3 review.

Expanded access in the meantime. Lilly's ClinicalTrials.gov listing NCT07629401, first posted June 5, 2026, offers single-patient pre-approval access to adults with a BMI of 35 or more, “at least two serious or life-threatening obesity-related complications,” obesity “refractory to the best approved therapy,” and no ability to join a retatrutide or comparable trial. Requests are initiated by the treating physician through the Lilly Answers Center, and availability “will depend on geography, product supply, and detailed individual eligibility assessment.”^[9]

Patient-facing summary: retatrutide will not be available by prescription in 2026, and realistically not until the FDA has reviewed an application Lilly plans to file in early 2027. Anyone telling you otherwise is speculating beyond what Lilly has publicly committed to.

Why retatrutide is NOT eligible for FDA-compliant compounding

FDA 503A compounding allows a state- licensed pharmacy to compound a drug for an individual patient based on a valid prescription, provided the bulk active ingredient is from an FDA- registered manufacturer AND meets one of three criteria: (1) it has a USP/NF monograph, (2) it is already an ingredient in an FDA-approved drug, or (3) it is on the FDA's 503A bulks list.

FDA 503B outsourcing facilities can compound drugs for office stock without patient-specific prescriptions provided the bulk API is on the 503B bulks list, OR the drug appears on the FDA Drug Shortage List.

Retatrutide qualifies under none of these pathways. Specifically:

• No USP/NF monograph exists for retatrutide. USP monographs are developed for established compendial drugs; investigational compounds are not on USP.
• Retatrutide is not a component of an FDA- approved drug. It is investigational. The triple- agonist molecular structure is novel.
• Retatrutide is not on the FDA 503A bulks list.
• Retatrutide is not on the 503B bulks list and is not on FDA's drug shortage list. (Tirzepatide and semaglutide were temporarily on the shortage list in 2023-2024, which is why compounded versions of those two drugs proliferated; both have since been removed from the shortage list and the compounding window has closed.)

FDA has issued Warning Letters to multiple compounders in 2024-2025 distributing retatrutide. The agency's position is unambiguous: retatrutide compounded in the US for human use outside an authorized clinical trial is unlawfully marketed.

The “research peptide” gray market — where we draw the line

Online retailers selling retatrutide as a “research peptide” or “not for human consumption” operate in a regulatory gray area that is not actually gray: shipping any non-FDA-approved drug across state lines for human use is a federal violation. The product itself carries multiple risks:

• No FDA-supervised manufacturing. Identity, purity, sterility, and potency are unverifiable.
• No FDA-supervised storage and handling. Peptide cold-chain is critical; shipping conditions are not validated.
• No FDA-supervised labeling. Dose and reconstitution instructions on gray-market vials may deviate materially from the trial protocols.
• Counterfeit risk. Independent testing of purchased gray-market peptides has repeatedly found underdosed, contaminated, or completely misidentified products.
• No clinical oversight. Self-administered investigational drugs without prescriber involvement forfeit the dose-titration, side-effect-monitoring, and contraindication-screening that the trials were designed around.
• Insurance and legal exposure. Patients presenting to emergency care after gray-market peptide adverse events face documentation and insurance coverage questions.

We do not name vendors, list URLs, or describe purchasing workflows for gray-market retatrutide. That is a hard line on this site. Patients seeking access to retatrutide in 2026 have two legitimate options: enroll in an active TRIUMPH Phase 3 trial (search clinicaltrials.gov by NCT ID) or use one of the FDA-approved alternatives until retatrutide gains FDA approval.

FDA-approved alternatives while waiting

Retatrutide's closest FDA-approved analog by mechanism is tirzepatide (Zepbound for weight management; Mounjaro for T2D), the dual GIP/GLP-1 agonist that is the parent class of retatrutide. Tirzepatide does not include glucagon-receptor agonism but covers two of the three retatrutide mechanisms and is the highest-effect-size FDA-approved AOM as of 2026, with SURMOUNT-1 (NEJM 2022, PMID 35658024) showing −20.9% mean body-weight loss at 15 mg vs −3.1% placebo at 72 weeks, and SURMOUNT-5 (NEJM 2025, PMID 40353578) confirming superiority over semaglutide head-to-head.

Other FDA-approved alternatives:

• Wegovy (semaglutide 2.4 mg, Novo Nordisk) — STEP-1 −14.9% at 68 weeks
• Foundayo (orforglipron, Lilly oral GLP-1) — ATTAIN-1 −11.1% at 17.2 mg/day at 72 weeks; a daily oral option without injection logistics
• Saxenda (liraglutide 3 mg, Novo Nordisk) — established but lower-effect-size GLP-1
• Qsymia (phentermine + topiramate ER) — non-GLP-1 oral combination, ~9.8% at top dose
• Full FDA-approved appetite-suppressant comparison

Bottom line

Retatrutide is the most-promising late-stage anti-obesity drug in development, with TRIUMPH-1 and TRIUMPH-2 now published (up to 25.0% and 18.8% weight loss at 80 weeks) and an FDA filing planned for the first quarter of 2027. It will not be available by prescription in 2026. Retatrutide is not eligible for FDA-compliant compounding under 503A or 503B; FDA has issued Warning Letters to multiple US compounders distributing it in 2024-2025. Patients seeking access have three legitimate options: clinical trial enrollment, physician-requested single-patient expanded access for those who meet its strict criteria (NCT07629401), or FDA-approved alternatives until retatrutide is approved. We do not name gray-market vendors.

Further reading

• Top retatrutide studies